Southern California Permanente Medical Group, Kaiser Permanente Southern California, San Diego Medical Center, San Diego, CA, USA.
Immunol Allergy Clin North Am. 2020 Nov;40(4):635-647. doi: 10.1016/j.iac.2020.06.003. Epub 2020 Sep 9.
Biologic and other therapies used for the treatment of immune-mediated hypersensitivity conditions, and in people with immune-mediated hypersensitivity, can trigger a wide variety of immune-related adverse drug reactions and immunologically mediated drug hypersensitivities. These range from acute-onset immunoglobulin E-mediated allergies to delayed-onset T-cell-mediated hypersensitivities. Certain therapeutic and diagnostic agents can directly activate mast cells. Biologic agents used to treat immune-mediated hypersensitivity can also globally upregulate or downregulate the immune system leading to pathologic reactions, including cytokine storm and hypogammaglobulinemia.
用于治疗免疫介导的过敏反应的生物制剂和其他疗法，以及用于免疫介导的过敏反应的患者，可引发各种免疫相关的药物不良反应和免疫介导的药物过敏。这些反应从急性发作的免疫球蛋白 E 介导的过敏反应到迟发性 T 细胞介导的过敏反应不等。某些治疗和诊断药物可直接激活肥大细胞。用于治疗免疫介导的过敏反应的生物制剂也可全面上调或下调免疫系统，导致病理反应，包括细胞因子风暴和低丙种球蛋白血症。
